Current status of sublingual immunotherapy in the United States
Sublingual immunotherapy (SLIT) use in the United States to date has been limited, despite common use and demonstrated efficacy elsewhere in the world. This is largely in part due to lack of FDA-approved SLIT products, lack of established dosing and administration guidelines, and cost concerns. Seve...
Main Authors: | Shelby Elenburg, Michael S. Blaiss |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-01-01
|
Series: | World Allergy Organization Journal |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455119302546 |
Similar Items
-
Current status of sublingual immunotherapy for allergic rhinitis in Japan
by: Keisuke Masuyama, et al.
Published: (2018-07-01) -
Sublingual Immunotherapy
by: Ferrell, Melissa Leann
Published: (2015) -
Sublingual immunotherapy in allergic asthma: Current evidence and needs to meet
by: Incorvaia Cristoforo, et al.
Published: (2010-01-01) -
Sublingual Immunotherapy: Recent Advances
by: Enrico Compalati, et al.
Published: (2013-01-01) -
Practice parameters for sublingual immunotherapy
by: C. Ortolani, et al.
Published: (2016-02-01)